Search for stocks /

Anthem Biosciences Ltd Q2 & H1 FY26 Concall Decoded – Molecules, Margins & Mega Ambitions!


1. Opening Hook

When biotech meets Bollywood ambition, you get Anthem — where every molecule dreams of becoming a blockbuster. Q2 FY26 was less about experiments in labs and more about experiments in scaling — Rs. 1,090 Cr revenue, 41% EBITDA margins, and enough new molecules to make the FDA blush. Management’s confidence? Sky-high. Their cash balance? Even higher.
But can Rs. 993 Cr in cash and 14 commercial molecules guarantee a stable petri dish of profits? Keep reading — the real chemistry starts when we talk about Unit-IV’s Rs. 1,000 Cr expansion and that juicy GLP-1 play. 🧪


2. At a Glance

  • Revenue ₹1,090 Cr (H1FY26) – Science fiction turned financial fact.
  • EBITDA ₹480 Cr, margin 41.4% – Every CFO’s version of “Eureka!”
  • PAT ₹309 Cr, margin 26.6% – Profits looking healthier than most clinical trials.
  • Cash ₹993 Cr – Cash-rich, risk-light; biotech’s rare mutation.
  • CRDMO revenue ₹926 Cr – Lab coats printing money.
  • Specialty Ingredients ₹163 Cr – Temporarily sacrificed at the altar of CDMO demand.
  • CAPEX ₹1,000 Cr (Unit-IV) – Because apparently, molecules need mansions. 🧬

3. Management’s Key Commentary

“We achieved ₹1,090 Cr revenue with 41.4% EBITDA margins.”
(Translation: We’re running a science lab like it’s a hedge fund.*)

“Specialty Ingredients slowed because CRDMO took over capacity.”
(Translation: When the main gig’s booming, side hustles wait their turn.*)

“Unit-II expansions (CP6 & CP7) add 130 KL capacity worth ₹300 Cr revenue potential.”
(Translation: Stainless steel tanks = growth machines.*)

“Unit-IV will cost ₹1,000 Cr and double capacity in 2 years.”
(Translation: Biotech’s version of a moonshot—literally and financially.*)

“Four new commercial molecules this half; total 14 now.”
(Translation: Molecules are the new product SKUs.*)

“EBITDA margins sustainable at 36–37%.”
(Translation: Unless the forex gods get grumpy.*)

“We’re building peptide and GLP-1 capabilities, fully integrated—no China fragments.”
(Translation: Anthem wants to own your next Ozempic addiction. 💉*)


4. Numbers Decoded

MetricQ2 & H1 FY26YoY ChangeManagement Spin
Revenue₹1,090 Cr+26%“Solid growth in every molecule.”
EBITDA₹480 Cr+20%“Operating leverage? Meet scientific leverage.”
EBITDA
Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!